Meglumine antimoniate is a medicine used to treat leishmaniasis.[1] This includes visceral, mucocutaneous, and cutaneous leishmaniasis.[1] It is given by injection into a muscle or into the area infected.[1]
Side effects include loss of appetite, nausea, abdominal pain, cough, feeling tired, muscle pain, irregular heartbeat, and kidney problems.[1] It should not be used in people with significant heart, liver, or kidney problems.[1] It is not recommended during breastfeeding.[1] It belongs to a group of medications known as the pentavalent antimonials.[1]
Meglumine antimoniate came into medical use in 1946.[2] It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[3] The wholesale cost in the developing world is about 4.32 USD per vial as of 2014.[4] It is available in Southern Europe and Latin America but not the United States.[5][6]
Society and culture
It is manufactured by Aventis[7] and sold as Glucantime in France, and Glucantim in Italy.
See also
Meglumine
References
^ abcdefgWHO Model Formulary 2008(PDF). World Health Organization. 2009. p. 183. ISBN 9789241547659. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
^Sneader, Walter (2005). Drug Discovery: A History. John Wiley & Sons. p. 59. ISBN 9780470015520. Archived from the original on 2016-12-20.
^"WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
^"Meglumine Antimonate". International Drug Price Indicator Guide. Retrieved 8 December 2016.
^Bope, Edward T.; Kellerman, Rick D.; Rakel, Robert E. (2010). Conn's Current Therapy 2011: Expert Consult. Elsevier Health Sciences. p. 95. ISBN 143773572X. Archived from the original on 2016-12-20.
^Gorbach, Sherwood L.; Bartlett, John G.; Blacklow, Neil R. (2004). Infectious Diseases. Lippincott Williams & Wilkins. p. 355. ISBN 9780781733717. Archived from the original on 2016-12-20.
^Aventis press release Archived 2014-05-22 at the Wayback Machine., 15 April 2005. (in German)
Actas dermo-sifiliograficas.Actas Dermosifiliogr.2015 May;106(4):310-316. doi: 10.1016/j.ad.2014.12.003. Epub 2015 Feb 10.
INTRODUCTION AND OBJECTIVES: Cutaneous leishmaniasis is the most common form of leishmaniasis, which is endemic in Spain. The aim of this study was to evaluate the epidemiological and clinical characteristics of cutaneous leishmaniasis seen in our hospital over a period of 20 years, with a particula
Successful treatment of cutaneous leishmaniasis with amphotericin B; a case of unresponsive to pentavalent antimony therapy.
Yeşilova Y1, Turan E, Altın Sürücü H, Aksoy M, Özbilgin A.
Türkiye parazitolojii dergisi / Türkiye Parazitoloji Derneği = Acta parasitologica Turcica / Turkish Society for Parasitology.Turkiye Parazitol Derg.2015 Mar;39(1):63-5. doi: 10.5152/tpd.2015.3761.
Cutaneous Leishmaniasis (CL) is a skin infection caused by various species of Leishmania parasites, which is transmitted by infected Phlebotomus sandfly bites. Pentavalent antimonials (meglumine antimoniate and sodium stibogluconate) are used for the treatment of adult CL patients as an effective an
Canine leishmaniosis caused by Leishmania infantum is still a common disease in endemic areas, such as the Mediterranean countries, and has progressively expanded into non-endemic areas like Central and Northern Europe. The aim of this article is to critically review current knowledge on the diagnos
